
The Cholesterol Test That's Often Missing from Standard Panels
ApoB (apolipoprotein B) is a protein on every cholesterol particle that can lodge in artery walls. It measures the number of harmful particles in your blood, which predicts heart attack risk far better than standard LDL cholesterol. We aim for ApoB under 80 mg/dL, lower for high-risk patients.
Beyond LDL: Why Philadelphia Needs an ApoB Strategy
Why is ApoB more accurate than LDL cholesterol?
ApoB is more accurate because it counts particles. Imagine your arteries as the Vine Street Expressway (I-676). Cholesterol (LDL-C) is the passengers in the cars. ApoB is the cars themselves. The number of cars on the road causes traffic jams (plaque), not how many people are riding inside. (For the "Mad Max" car analogy that explains Lp(a), see our Lp(a) article.) You can have low cholesterol (few passengers) but high ApoB (many small cars). This is called discordance, and it is the single biggest missed warning in modern cardiology.
Why isn't ApoB on standard panels?
ApoB is not on most standard panels because the system is built for disease management, not prevention. In a typical 15-minute insurance-based visit, doctors are pushed to follow guidelines based on 10-year risk models that activate after a problem starts. We worked in that system. We followed those guidelines until the data on early atherosclerosis (plaque buildup) became impossible to ignore. At Fishtown Medicine, we have time, and we are free from insurance denial algorithms. That lets us practice Medicine 3.0, treating risk decades before it becomes a heart attack.What is the Fishtown ApoB strategy?
Our ApoB strategy treats your arteries like a long-term retirement account: early investment compounds.1. The Audit (ApoB and Lp(a))
We measure the actual drivers of disease.- ApoB: The total particle count. Target under 80 mg/dL for most adults, under 60 for high risk, and closer to 30 for very high risk.
- Lp(a): A genetic heart attack marker. You only need to test it once. If it is high, we treat your other numbers more carefully no matter what they show.
2. The Verification (CTA and Cleerly AI)
Blood work is probability. Imaging is proof. A coronary artery calcium (CAC) score misses the most dangerous plaque. It only sees calcified, hardened plaque and skips soft, vulnerable plaque, which is the type that causes most sudden heart attacks. A CAC of zero can give false reassurance. We urge eligible patients to consider a CT Coronary Angiogram (CTA) with Cleerly AI analysis. It quantifies both calcified and soft plaque, so we see disease before it hardens or ruptures.3. The Architecture (Intervention)
We build a plan to drive ApoB down because ApoB has a causal link to heart disease. This is not just a correlation. It is the mechanism of injury. We believe atherosclerotic heart disease should sit at the 20th leading cause of death, not the 1st. It is largely preventable.- Nutrition: Fiber-rich foods and reasonable saturated fat limits, customized to your genetics.
- Pharmacology: We use tools like statins, PCSK9 inhibitors, or bempedoic acid when lifestyle alone is not enough. We treat to a target.
Actionable Steps in Philly
Build a real ApoB strategy.- Get an ApoB test. Add it to your next blood draw. The cash price is usually $20 to $40 if it is not covered.
- Check Lp(a) once. Pair it with your ApoB. One test, lifelong information.
- Know your target. Most adults aim for ApoB under 80 mg/dL. Ask us what target fits your risk.
- Image when it changes the plan. If your ApoB or family history is high, a Cleerly CTA shows soft plaque before it ruptures.
Key Takeaways
- Test Early: Plaque can start forming in the 20s. The earlier we lower ApoB, the more compounding protection you build.
- Demand Lp(a): Every adult should know their Lp(a) status. It can drive heart attacks in people who "did everything right."
- Insulin Matters: Insulin resistance, when cells stop responding well to insulin, makes LDL particles smaller and more harmful. Fixing the metabolism helps fix the heart.
Scientific References
- Sniderman AD, et al. "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review." JAMA Cardiology. 2019.
- Marston NA, et al. "Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction." JAMA Cardiology. 2022.
- Nissen SE, et al. "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients." New England Journal of Medicine. 2023.
- Min JK, et al. "Coronary CTA-derived plaque characteristics and the prediction of major adverse cardiovascular events." JACC: Cardiovascular Imaging. 2022.
Related Articles:
Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. He practices Medicine 3.0 preventive cardiology so your heart lasts as long as your ambition.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Still have a question?
He answers personally. Usually within a few hours.
Related Intelligence

Longevity Strategies | Fishtown Medicine
Strategies to extend your healthspan and optimize lifespan in Philadelphia.

Metabolic Health
Why you feel tired at 3 PM, and how to fix it.

The Future of Medicine 3.0: Stewardship of the 100-Year Life
We are at an inflection point. Discover the shift from analog 'sick care' to digital, predictive, and participatory health stewardship for a 100-year life.
Talk it through with Dr. Ash.
If anything you read here raised a question, this is a free 20-minute Warm Invitation Call. Pick a time and we’ll work through it together.
Loading scheduler...
Having trouble with the scheduler? Book directly on Dr. Ash’s calendar
